Obesity Drugs Go Back To The Drawing Board; FDA To Hold Advisory Committee On CV Risk
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
FDA will conduct an advisory committee early in 2012 to discuss how to assess the cardiovascular risk of weight-loss drugs, Orexigen revealed June 3 in announcing the firm will halt development in the U.S. of its obesity medication Contrave.
You may also be interested in...
FDA Holds To High Standards For Insomnia Drugs With Second “Complete Response” For Transcept’s Intermezzo
FDA’s second “complete response” letter for Transcept Pharmaceuticals’s Intermezzo continues the strict scrutiny the agency has given recent candidates for sleep maintenance insomnia indications.
FDA Holds To High Standards For Insomnia Drugs With Second “Complete Response” For Transcept’s Intermezzo
FDA’s second “complete response” letter for Transcept Pharmaceuticals’s Intermezzo continues the strict scrutiny the agency has given recent candidates for sleep maintenance insomnia indications.
Losing The Battle Of The Bulge: FDA Holds Up Orexigen's Contrave
The Contrave "complete response" letter could mean research in the category is sidelined now that all three of the current obesity drug candidates have been rejected.